Perspective Therapeutics’ [212Pb]VMT01 Melanoma Data Accepted for Presentation at 2026 SITC Annual Meeting
Perspective Therapeutics announced that data for its lapemelanotide zapixetar ([212Pb]VMT01) program, a treatment for unresectable or metastatic melanoma, has been accepted for presentation at the 2026 Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting. The data comes from a Phase I/IIa trial, highlighting that the treatment was well-tolerated and showed promising disease stabilization in a significant percentage of patients, with two responders out of seven in the monotherapy cohort. The company is advancing its radiopharmaceuticals and expanding its drug supply network, focusing on personalized cancer treatment.
A study of a targeted melanoma treatment will be presented at a cancer meeting in November.
Perspective Therapeutics (CATX) announced that data from its [212Pb]VMT01 melanoma program has been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in November 2026. The Phase I/IIa trial poster details results for treatment alone and in combination with nivolumab. Interim ASCO data showed two responders out of seven patients in the 3.0 mCi monotherapy cohort, with 86% experiencing stable disease or partial response, and no dose-limiting toxicities.
Three cancer programs are in trials. Perspective Therapeutics (CATX) reports early melanoma results.
Perspective Therapeutics (CATX) has updated its corporate presentation, detailing its radiopharmaceutical oncology pipeline which includes three clinical-stage programs: VMT-α-NET, VMT01, and PSV359. These programs target distinct solid tumors, addressing a combined market estimated at over $45 billion, with data expected in 2026 from ongoing Phase 1/2a studies. Early results for VMT01 in melanoma show anti-tumor activity at a 3.0 mCi dose, and VMT-α-NET's profile suggests it could support a potential registration study.
Form 8K Perspective Therapeutics Inc For: 1 October By Investing.com
The article reports on a Form 8K filing by Perspective Therapeutics Inc. for October 1st. It also briefly mentions the company's stock ticker, CATX, and its performance for the day. The core content is a very short announcement from Investing.com.
Form 8K Perspective Therapeutics Inc For: 1 October By Investing.com
This article announces that Perspective Therapeutics Inc. filed a Form 8K on October 1st. It also includes a stock performance update for CATX, showing a -1.09% change. The content appears to be a brief financial news item from Investing.com.
Form 13D/A Perspective Therapeutics For: 26 September By Investing.com
This article reports on a Form 13D/A filing for Perspective Therapeutics, dated September 26th. It notes that the filing is available through Investing.com and was published on September 27, 2026. The piece also includes a mention of CATX stock performance, showing a -0.79% change.
Form 13D/A Perspective Therapeutics For: 26 September By Investing.com
This article reports on the filing of a Form 13D/A by Perspective Therapeutics, dated September 26. The brief announcement, published by Investing.com, likely pertains to changes in beneficial ownership of the company's shares. It is a direct factual report of a regulatory filing.
Form 13D/A Perspective Therapeutics For: 26 September
This article reports on the filing of Form 13D/A for Perspective Therapeutics, dated September 26th. Form 13D/A is an amendment to a Schedule 13D filing, which indicates a beneficial ownership of more than 5% of a company's stock by an individual or group. The document's specifics are not detailed in this brief announcement.
Perspective Therapeutics (CATX) Short Interest & Short Float | Updated Sep 2026
This article provides an updated report on Perspective Therapeutics (CATX) short interest as of September 2026. It details that 22.81 million shares were sold short, representing 20.59% of the public float, marking a 2.34% decrease from the previous report. The short interest ratio is 16.9 days to cover, indicating a high level of pessimism among investors.
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiated coverage on Perspective Therapeutics (NYSE: CATX) with an Outperform rating, seeing significant upside potential. Analyst Andy Hsieh believes the company is well-positioned in the growing radiopharmaceutical cancer treatment market, which could reach $35 billion in the U.S. alone. The firm estimates a fair value of $11.45 per share for CATX, compared to its recent price of $2.70, suggesting Wall Street is underestimating its platform's potential.
Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index
Perspective Therapeutics, Inc. (NYSEAM:CATX) has been removed from the S&P Biotechnology Select Industry Index. This news follows several other recent updates for the company, including a new "Outperform" rating from William Blair and a clinical collaboration with Merck.
William Blair Initiates Perspective Therapeutics(CATX.US) With Buy Rating
William Blair has initiated coverage of Perspective Therapeutics (CATX.US) with a Buy rating. This rating indicates a positive outlook from the firm regarding the company's stock.
William Blair initiates Perspective Therapeutics stock with outperform rating
William Blair initiated coverage on Perspective Therapeutics Inc (NYSE: CATX) with an outperform rating, citing the company's strong position in lead-212-based radiopharmaceuticals and its peptide platform. Analysts see substantial upside potential with price targets ranging from $5 to $18, reinforced by recent upward earnings revisions from six analysts. Other firms like BMO Capital, Piper Sandler, and BTIG have also issued positive ratings, highlighting the company's manufacturing capabilities and strategic plans.
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiated coverage on Perspective Therapeutics Inc. (CATX) with an Outperform rating, citing the company's strong position in the growing radiopharmaceutical cancer treatment market. The analyst estimates a probability-adjusted fair value of $11.45 per share, significantly higher than its recent trading price, due to the industry's rapid expansion and underestimated clinical potential of Perspective's platform.
William Blair initiates Perspective Therapeutics stock with outperform rating By Investing.com
William Blair initiated coverage on Perspective Therapeutics Inc (NYSE: CATX) with an outperform rating, citing the company's strong position in lead-212-based radiopharmaceuticals, its peptide platform, and established supply chain. Analysts see substantial upside potential with price targets ranging from $5 to $18. The firm highlighted the potential for a highly tolerable radiopharmaceutical with reduced kidney toxicity and estimates the radiopharmaceutical market could reach roughly $35 billion.
Merck joins Perspective Therapeutics (NYSE: CATX) to test Keytruda combo in Phase 1/2a cancer trial
Perspective Therapeutics announced a collaboration with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Merck's Keytruda (pembrolizumab) for FAP-α–positive solid tumors. This combination will be studied as an amendment to Perspective's ongoing Phase 1/2a trial for non-small cell lung and colorectal cancers. Perspective will sponsor the study, with Merck supplying Keytruda at no cost, aiming to improve treatment outcomes by reshaping the tumor environment.
Perspective Therapeutics partners with Merck on cancer trial By Investing.com
Perspective Therapeutics announced a clinical trial collaboration with Merck to evaluate a combination cancer therapy. The trial will test Perspective's targeted alpha-particle therapy, [212Pb]PSV359, with Merck's Keytruda for non-small cell lung cancer and colorectal cancer patients expressing FAP-α. Perspective will sponsor the study, with Merck providing pembrolizumab at no cost, focusing on safety and tolerability to determine the optimal Phase 2 dose.
Perspective Therapeutics partners with Merck on cancer trial
Perspective Therapeutics announced a clinical trial collaboration with Merck to evaluate the combination of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 with Merck’s Keytruda for non-small cell lung cancer and colorectal cancer. The collaboration will amend Perspective's ongoing Phase 1/2a study, with Merck providing pembrolizumab at no cost. The study aims to determine the recommended Phase 2 dose for PSV359, which targets FAP-α expressed in solid tumors.
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
Perspective Therapeutics has announced a clinical collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy, [212Pb]PSV359, in combination with Merck's Keytruda® (pembrolizumab). This collaboration aims to assess the combination therapy in patients with FAP-α positive solid tumors, particularly in non-small cell lung cancer and colorectal cancer, building on Perspective's ongoing Phase 1/2a study. The goal is to improve treatment outcomes by potentially reshaping the tumor microenvironment through this combined approach.
Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell
Perspective Therapeutics announced a clinical trial collaboration with Merck (MSD) for cancer treatment, which led to a pre-bell increase in its shares. The company specializes in radiopharmaceutical development, using alpha-emitting isotopes for targeted cancer therapy and imaging diagnostics. This collaboration aims to advance their proprietary technology for treating various cancers.
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
Perspective Therapeutics announced that updated data from its [212Pb]VMT-α-NET program have been accepted for presentation at the 38th EORTC-NCI-AACR Symposium in November 2026. The presentation will detail cohort-level safety and efficacy results for the treatment in advanced neuroendocrine tumors. This radiopharmaceutical treatment is designed to target SSTR2-expressing tumors with the alpha-emitting radioisotope lead-212.
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
Perspective Therapeutics announced that updated data from its [212Pb]VMT-α-NET program, which targets neuroendocrine tumors, has been accepted for presentation at the 38th EORTC-NCI-AACR Symposium in November 2026. The presentation will detail cohort-level safety and efficacy results for advanced SSTR2-expressing neuroendocrine tumors. This radiopharmaceutical development company is pioneering advanced treatments using alpha-emitting radioisotopes for various cancers.
Perspective Therapeutics Announces Acceptance of Updated [212Pb]VMT-α-NET Data for Presentation at 2026 ENA Symposium | CATX Stock News
Perspective Therapeutics, Inc. announced that updated data from its [212Pb]VMT-α-NET program for neuroendocrine tumors will be presented at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain, from November 18 to 20, 2026. The presentation will detail cohort-level safety and efficacy results for patients with advanced SSTR2-expressing neuroendocrine tumors who have not received prior radiopharmaceutical therapies. The company is advancing a portfolio of clinical-stage programs using its proprietary alpha-generating isotope 212Pb technology and expanding its drug product supply network for future clinical trials and potential commercial operations.
Perspective Therapeutics (CATX) highlights 3 cancer drug programs
Perspective Therapeutics (CATX) updated its corporate presentation, emphasizing its strategy in next-generation radiopharmaceutical therapy for oncology. The company highlighted three clinical-stage programs (VMT-α-NET, VMT01, and PSV359) targeting distinct cancer types, addressing an estimated $45 billion+ market. Clinical data, including ASCO 2026 analyses, are expected in 2026, supported by an integrated platform for isotope production and manufacturing.
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock
Lantheus Holdings, a significant owner of Perspective Therapeutics (CATX), sold 78,145 shares worth $245,609 on August 31, 2026. Despite this insider sale, analysts maintain a strong buy consensus for CATX with considerable upside potential, and the company has recently received positive analyst coverage from BMO Capital, Piper Sandler, and BTIG. The sale follows a 42% decline in CATX stock over the past six months, though it has gained 13% year-to-date.
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Perspective Therapeutics, Inc. announced it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026, after the market closes. The company, a radiopharmaceutical developer, is pioneering advanced treatments for cancers using its proprietary alpha-generating isotope 212 Pb technology. It is also expanding its regional finished drug product candidate supply network to support clinical trials and commercial operations.
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Perspective Therapeutics (CATX) has experienced a bearish trend, but a recent hammer chart pattern suggests a potential trend reversal. This technical indicator, combined with rising optimism among Wall Street analysts regarding the company's future earnings and its Zacks Rank #2 (Buy), points to an impending upward movement for the stock. Investors are advised to consider CATX as bulls may soon gain control, driving the price up.
BMO Capital Markets Upgrades Perspective Therapeutics (NYSEAMERICAN:CATX) to "Strong-Buy"
BMO Capital Markets has upgraded Perspective Therapeutics (NYSEAMERICAN:CATX) to a "strong-buy" rating, while the broader analyst consensus remains "buy" with an average price target of $11.50. Despite mixed recent analyst actions and slightly below-forecast revenue, the company beat quarterly EPS expectations. Institutional investors own 54.66% of the stock, with several increasing their stakes.
BMO Capital Initiates Perspective Therapeutics at Outperform
BMO Capital has initiated coverage on Perspective Therapeutics with an Outperform rating. This signals a positive outlook from the firm regarding the company's future performance.
PERSPECTIVE THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $11
BMO Capital Markets has initiated coverage on Perspective Therapeutics Inc. (CATX.A) with an Outperform rating. The firm has also set a price target of $11 for the company's stock. This indicates a positive outlook from BMO regarding Perspective Therapeutics' future performance.
Perspective Therapeutics Market Sentiment
This article provides an overview of market sentiment for Perspective Therapeutics (CATX), including analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 17 analysts with an average price target of $11, a short interest of 24.6%, and details recent analyst actions with various ratings and price target revisions.
BMO initiates Perspective Therapeutics stock at Outperform, $11 target
BMO Capital has initiated coverage on Perspective Therapeutics Inc. (NYSE:CATX) with an Outperform rating and an $11 price target, citing substantial upside potential from its current $3.21 stock price. The firm highlighted the company's proprietary lead-212 platform for radioligand therapies and its pipeline, including bamzireotide navoxetan, as key differentiators. This positive outlook is supported by recent upward earnings revisions from analysts and promising clinical data for its assets.
Perspective Therapeutics Price Target Announced at $11.00/Share by BMO Capital
BMO Capital has set a price target of $11.00 per share for Perspective Therapeutics (NYSEAMERICAN:CATX). This indicates a significant potential upside for the stock from its current trading levels. This news may be of interest to investors following the biotechnology and pharmaceutical sectors.
BMO Capital Initiates Perspective Therapeutics at Outperform
BMO Capital has initiated coverage on Perspective Therapeutics (CATX) with an "Outperform" rating. The company, a radiopharmaceutical developer, focuses on advanced cancer treatments using the alpha-emitting isotope 212Pb and imaging diagnostics. This initiation follows several recent developments for Perspective Therapeutics, including BofA Securities adjusting its price target and progress in its clinical trials for neuroendocrine tumors and meningioma.
BMO initiates Perspective Therapeutics stock at Outperform, $11 target
BMO Capital has initiated coverage on Perspective Therapeutics Inc. (NYSE:CATX) with an Outperform rating and an $11 price target, indicating significant upside potential. The company specializes in precision radioligand therapies, with its lead program, bamzireotide navoxetan, targeting neuroendocrine tumors. This positive outlook is supported by promising clinical data and recent analyst revisions, despite a slight adjustment in price target from Piper Sandler, and continued endorsement from BTIG.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has received a "Moderate Buy" consensus recommendation from analysts, with eight buy ratings and one hold out of nine analysts. The average 12-month price target for the stock is $11.56, significantly higher than its recent trading price of $3.22. The company reported a quarterly loss of $0.22 per share, beating analyst estimates, and institutional investors own 54.66% of its stock.
BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6
BofA Securities has lowered its price target for Perspective Therapeutics (NYSEAMERICAN:CATX) to $5, down from the previous target of $6. The firm has maintained its Buy rating on the company's stock.
Bank of America Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $5.00
Bank of America has lowered its price target for Perspective Therapeutics (NYSEAMERICAN:CATX) to $5.00 from $6.00, while maintaining a neutral rating, implying a potential upside of 56.99%. Despite this, analyst sentiment remains broadly positive with a "Moderate Buy" consensus and an average target price of $11.56. The company recently reported a narrower-than-expected quarterly loss but continues to post substantial losses as it develops early-stage cancer therapies.
Perspective Therapeutics: Q2 Earnings Snapshot
This article provides a brief "Q2 Earnings Snapshot" for Perspective Therapeutics. However, the content itself is minimal, consisting only of a "Powered and protected by Privacy" statement, suggesting that the actual earnings data is missing or was not captured.
BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6
BofA Securities has lowered its price target for Perspective Therapeutics (CATX) from $6 to $5, according to a report published on August 14, 2026. This adjustment comes as the radiopharmaceutical development company continues its work on advanced cancer treatments. The article also mentions recent news about Perspective Therapeutics, including data on its NET program and its neuroendocrine tumor therapy receiving EU Orphan Drug Designation.
Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX
Dimensional Fund Advisors LP significantly increased its stake in Perspective Therapeutics, Inc. (CATX) by 391.6% in the first quarter, purchasing an additional 358,540 shares to hold a total of 450,097 shares valued at $1.88 million. Despite CATX stock recently trading down 4.9% at $3.10, institutional investors collectively own 54.66% of the company, and analysts maintain a consensus "Buy" rating with an average price target of $12.38. The company, which is advancing precision-targeted alpha therapies for cancer treatment, also reported a quarterly loss of $0.22 per share, outperforming estimates.
Perspective Therapeutics (CATX): Millennium group reports over 5% beneficial stake
Millennium Management LLC and affiliated entities have reported an amended beneficial ownership stake in Perspective Therapeutics (CATX). Integrated Core Strategies (US) LLC holds 5.2% of common stock, while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 5.5% of the outstanding common stock. All reported shares indicate shared voting and dispositive power, with no sole voting or dispositive power claimed by any of the reporting persons.
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer
Oppenheimer analyst Jeff Jones reiterated a Buy rating on Perspective Therapeutics (CATX) with a $13.00 price target, based on his 5-star analyst track record. The company's Q1 earnings showed a revenue of $76 thousand and a GAAP net loss of $26.19 million. The analyst consensus for CATX is a Strong Buy with an average price target of $12.78.
Perspective Therapeutics: Q2 Earnings Snapshot
This article provides a brief "snapshot" of Perspective Therapeutics' Q2 earnings. No specific financial details or further information about the earnings are provided in the current content.
Piper Sandler cuts Perspective Therapeutics price target on timing
Piper Sandler has reduced its price target for Perspective Therapeutics (NYSE:CATX) to $14 from $16, while maintaining an Overweight rating, due to anticipated timing of clinical trial milestones. The company reaffirmed that pivotal site activation for bamzireotide navoxetan is expected around year-end 2026, and data for VMT01 are also expected in late 2026, while the next update for PSV359 has moved to 2027. Despite the price target adjustment, other analysts like RBC Capital and BTIG have reiterated positive ratings and price targets for Perspective Therapeutics, citing ongoing clinical developments and competitive advantages.
CATX Maintained by Piper Sandler -- Price Target Lowered to $14.
Piper Sandler has maintained an Overweight rating for Perspective Therapeutics Inc (CATX) but lowered its price target to $14.00 from $16.00, indicating a cautious outlook despite positive sentiment. CATX, operating in the radiopharmaceuticals sector, currently has a GF Score™ of 30/100, highlighting concerns regarding its profitability and growth, and appears overvalued based on its Price-to-Sales ratio. Guru and insider activity show mixed sentiment, with some increasing and others trimming positions.
Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Lowered to $14.00 at Piper Sandler
Piper Sandler has lowered its price target for Perspective Therapeutics (NYSEAMERICAN:CATX) to $14.00 from $16.00, while maintaining an "overweight" rating. This new target suggests a significant upside of 366.67% from the current stock price of $3.00. The company recently reported a narrower-than-expected quarterly loss of $0.22 per share, although revenue slightly missed estimates.
Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results
Perspective Therapeutics (NYSEAMERICAN:CATX) reported its quarterly earnings, beating analyst expectations with a loss of $0.22 per share against a consensus of $0.27, although revenue of $0.08 million was slightly below the $0.09 million estimate. The company's shares remained flat at $3.00, and institutional investors hold a significant portion of its stock. Analysts maintain a "Buy" rating with a consensus price target of $12.62 as the company progresses with its precision-targeted cancer therapies through clinical trials.
Perspective Therapeutics: Q2 Earnings Snapshot
This article provides a brief "snapshot" of Perspective Therapeutics' Q2 earnings. Due to the limited content, no detailed financial figures or specific performance indicators are available beyond the headline.
Perspective Therapeutics (NYSE: CATX) grows cash to $237M while advancing Phase 3-ready pipeline
Perspective Therapeutics announced its second-quarter 2026 results, reporting a significant increase in cash reserves to $237 million, up from $145 million at the end of 2025, which is expected to fund operations into late 2027. The company is progressing its lead candidate, VMT-α-NET, towards a Phase 3 study for neuroendocrine tumors with site activation anticipated around year-end 2026, subject to regulatory feedback. Despite an increased net loss of $26.8 million due to higher R&D expenses, the company continues to expand its radiopharmaceutical manufacturing network and advance other clinical programs.
